1 FTSE 250 stock I’d consider buying for the boom in private healthcare!

This FTSE 250 company continues to grow its top and bottom lines as it helps the NHS clear the huge backlog of cases.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One growth market in the UK in recent years has been private healthcare insurance. A handful of FTSE companies are benefitting from this rising trend, including insurance giant Aviva. Last year, the firm reported that its health insurance sales surged 41%.

Aviva CEO Amanada Blanc said: “We’ve seen individuals looking at the NHS and saying: ‘I can afford to buy health cover, so I will do that.’ So we’ve definitely seen a take-up in individual policies. We’ve also seen small businesses take advantage of the opportunity to protect their employees.”

That’s a reference, of course, to the NHS’s massive backlog of cases. In June, the waiting list reached 7.62m, with the median waiting time for treatment at 14.3 weeks (almost double the pre-pandemic wait).

Should you invest £1,000 in Spire Healthcare right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Spire Healthcare made the list?

See the 6 stocks

The new government has called the NHS a “broken” system (though not “beaten“) following years of underinvestment. Things aren’t expected to improve anytime soon, especially with budget pressures and a rapidly rising (and ageing) population.

So the steady growth of private healthcare, which is carrying out more outsourced work for the NHS, seems almost certain. Here’s one FTSE 250 stock that offers investors direct exposure to the trend.

Booming demand

Spire Healthcare Group‘s (LSE: SPI) the second-largest provider of private healthcare in the UK. It runs 38 hospitals and over 50 clinics, medical centres and consulting rooms.

The share price is up 84% in five years, giving the firm a £903m market-cap.

Created with Highcharts 11.4.3Spire Healthcare Group Plc PriceZoom1M3M6MYTD1Y5Y10YALL28 Oct 201928 Oct 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

The company’s carrying out more work for the NHS and benefitting from both people and businesses paying to avoid long waiting lists. In 2023, revenue rose 13.4% to £1.35bn, while adjusted pre-tax profit rocketed 175% to £38.8m. Free cash flow increased 71.4% to £48m.

This strong performance continued into the first half of 2024. Spire’s revenue rose 12.7% to £762.5m, and adjusted pre-tax profit jumped 20.2% to £26.8m. Growth was boosted by the acquisition of Vita Health Group, a leading provider of mental and physical health services.

NHS revenue increased 5.2%, and the average revenue per case rose 4.7% to £3,495.

For the full year, revenue’s set to jump around 12.3% to £1.53bn. And the firm’s now fully staffed at almost all sites, which should help reduce the need for expensive agency staff. 

CEO Justin Ash said: “Spire stands ready to work with the new government to help address NHS waiting lists.”

Valuation

Looking further ahead, forecasts show steady if unspectacular growth through to 2026.

Revenue
2023£1.35bn
2024£1.53bn
2025£1.62bn
2026£1.72bn

One risk here would be a government U-turn on using the private sector to bring down NHS waiting lists. This doesn’t look likely to me, but it can’t be ruled out.

Another issue is that the stock looks expensive, trading at 26 times trailing earnings. However, analysts see profits growing much faster than revenue, resulting in a cheap forward earnings multiple of 11 for 2026.

There’s also a dividend set to grow rapidly, though the yield‘s currently tiny at just under 1%.

Pure-play stock

According to Spire, more young people than ever are opting for private health insurance. This suggests going private could become the norm for a new generation, even after NHS waiting lists are reduced.

If I wanted pureplay exposure to this theme in my portfolio and had the cash, I’d consider buying shares of Spire Healthcare.

Pound coins for sale — 31 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Aviva Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£20K invested in Tesla stock last April is now worth…

Despite all the bad headlines lately, Tesla stock has put in a storming performance over a 12-month timeframe. Is this…

Read more »

Investing Articles

If a 40 year old invests £600 a month in a SIPP, here’s what they could have by retirement

With no retirement savings at 40, an investor could put £600 a month into a SIPP and grow its value…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Why hasn’t its 9.9% yield boosted the Phoenix share price?

Phoenix Group has a dividend close to double digits, but saw a weak share price performance in recent years. Christopher…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

With average 10% yields, these mid-cap FTSE shares could supercharge a passive income portfolio

Some of the best passive income gems can be found on the UK's smaller indexes like the FTSE 250 and…

Read more »

A coin being dropped into a piggy bank
Investing Articles

As the Barclays share price tanks 19% in 2 days, is this a great buying opportunity?

As a trade war sends the Barclays share price into a tailspin, Andrew Mackie steps back to look at the…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is Fundsmith Equity still a good choice for a Stocks and Shares ISA in 2025?

Many Britons hold the Fundsmith Equity fund in their Stocks and Shares ISAs. Is this still a good move? Edward…

Read more »

Investing Articles

Nvidia stock is down 24% this year. Time to buy the dip?

Christopher Ruane has been eyeing Nvidia stock as a potential addition to his portfolio for a while. Is a recent…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Down 25% since January, this resilient dividend stock’s catching my eye

Maintaining the UK’s rail, water, and energy infrastructure isn’t the most exciting business. But it has made this a solid…

Read more »